TRPV1

Human medicines European public assessment report (EPAR): Qutenza, capsaicin, Date of authorisation: 15/05/2009, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Capsaicin, Marketing, European Commission, INN, HIV/AIDS, Infection, Diabetic neuropathy, ATC, Pain, Varicella zoster virus, International, European, Diabetes, Language, Shingles, Red, TRPV1, Trigeminal neuralgia, Neuropathic pain, HIV, Select, Committee, Patient, Risk management, Anatomy, Medicine, IIA, CHMP, Skin, Medical device

Human medicines European public assessment report (EPAR): Qutenza, capsaicin, Date of authorisation: 15/05/2009, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Qutenza, capsaicin, Date of authorisation: 15/05/2009, Revision: 19, Status: Authorised

Bsense Announces the Clinical Candidate Nomination of BSEN760, a Novel Dual Kv7.2/3 and TRPV1 Modulator, to Unlock a New Approach to Dampening Sensory Hyperexcitability for Chronic Pain Treatment

Retrieved on: 
Tuesday, December 5, 2023
MOA, Principal, Pain, Chronic pain, Therapy, Diabetic neuropathy, TRPV1, Temperature, CNS, SOC, NESS, Pharmaceutical industry

BSEN760 is a novel potent and selective, orally active, investigational small molecule drug that simultaneously activates Kv7.2/3 and inhibits TRPV1.

Key Points: 
  • BSEN760 is a novel potent and selective, orally active, investigational small molecule drug that simultaneously activates Kv7.2/3 and inhibits TRPV1.
  • The dual mechanism of action (MOA) of BSEN760 underlies the compound’s exquisite potency and synergistic activity in dampening sensory neuron hyperexcitability.
  • As such, BSEN760 may enter the market with comparable, potentially better, efficacy vs. SOC, and a much improved safety profile.
  • These, and other data, support the Company’s efforts toward full preclinical development of BSEN760 and IND submission by Q1 2025.

MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain

Retrieved on: 
Thursday, October 19, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, TRPV1, Burns, System, MD, Inflammation, DEA, Pain, Hypoesthesia, Injury, Controlled Substances Act, Pain management, Shingles, Diabetic neuropathy, Disability, CSA, Pharmaceutical industry, CBD

MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, today announced results from a preclinical study of its investigational cannabinoid Supera-CBD™, a novel, synthetic, non-toxic cannabidiol (CBD) analog.

Key Points: 
  • MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, today announced results from a preclinical study of its investigational cannabinoid Supera-CBD™, a novel, synthetic, non-toxic cannabidiol (CBD) analog.
  • In the study, Supera-CBD targeted and quickly reduced inflammatory pain within 60 minutes, providing pain relief for up to five hours.
  • Comparatively, traditional CBD had no effect on this type of pain in the same study.
  • “These preclinical results illustrate the potential of Supera-CBD to alleviate acute inflammatory pain related to injuries, burns, surgery, and flare-ups from chronic inflammatory conditions such as diabetic neuropathy and shingles,” said Chris Chapman, MD, president, director and chief medical officer, MyMD.

Team from Korea University Medicine Explores Ways to Overcome Cisplatin Resistance and Alleviate Pain in Cancer Treatment

Retrieved on: 
Friday, July 21, 2023
Neoplasm, NANOG, Nature Communications, TRPV1, Epidermal growth factor, Cisplatin, EGF, Transcriptome, Drug resistance, Cervical cancer, Patient, EGFR, Neuropathic pain, Cancer, Attention deficit hyperactivity disorder predominantly inattentive, Metastasis, Platinum, Vaccine

SEOUL, South Korea, July 21, 2023 /PRNewswire/ -- Cisplatin is a widely used chemotherapy drug for various types of cancers. However, frequent usage can lead to the development of drug resistance and neuropathic pain, eventually resulting in treatment failure. In a new study, researchers from South Korea investigated the underlying pathways contributing to this resistance and identified potential therapeutic targets that can be modulated to overcome this. By understanding and targeting these mechanisms, effective treatment strategies can be developed and implemented.

Key Points: 
  • However, frequent usage can lead to the development of drug resistance and neuropathic pain, eventually resulting in treatment failure.
  • But the continued use of cisplatin can lead to the development of cisplatin resistance and other side effects, like chemotherapy-induced neuropathic pain.
  • Now, in a new study, Prof. Tae Woo Kim from Korea University Medicine and his team have explored the pathways leading to cisplatin resistance.
  • This study serves as valuable proof-of-concept for TRPV1 as a therapeutic target to combat cisplatin resistance and neuropathic pain, thereby improving the outlook for patients with cervical cancer.

Grünenthal's resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee

Retrieved on: 
Monday, May 22, 2023
Osteoarthritis, Nobel Prize, Disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Transience, Shionogi, Marketing, Perception, Breakthrough therapy, TRPV1, Temperature, II, Pain, OA, Acquisition, Patient, European, Joint, Nobel Prize in Physiology or Medicine, System, FDA, Breakthrough, RTX, Food, Safety, Knee, Pharmaceutical industry, Medicine, Physiology

Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain.

Key Points: 
  • Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain.
  • Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid therapy, in adults with pain associated with knee osteoarthritis.
  • AACHEN, Germany, May 22, 2023 /PRNewswire/ -- Grünenthal today announced that its investigational non-opioid medicine resiniferatoxin (RTX), currently undergoing clinical Phase III development, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for pain associated with osteoarthritis (OA) of the knee.
  • We are hopeful that the Breakthrough Therapy Designation will help us to bring this non-opioid therapy option more quickly to patients."

Grünenthal's resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee

Retrieved on: 
Monday, May 22, 2023
Osteoarthritis, Nobel Prize, Disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Transience, Shionogi, Marketing, Perception, Breakthrough therapy, TRPV1, Temperature, II, Pain, OA, Acquisition, Patient, European, Joint, Nobel Prize in Physiology or Medicine, System, FDA, Breakthrough, RTX, Food, Safety, Knee, Pharmaceutical industry, Medicine, Physiology

Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain.

Key Points: 
  • Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain.
  • Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid therapy, in adults with pain associated with knee osteoarthritis.
  • AACHEN, Germany, May 22, 2023 /PRNewswire/ -- Grünenthal today announced that its investigational non-opioid medicine resiniferatoxin (RTX), currently undergoing clinical Phase III development, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for pain associated with osteoarthritis (OA) of the knee.
  • We are hopeful that the Breakthrough Therapy Designation will help us to bring this non-opioid therapy option more quickly to patients."

Kanazawa University research: Experiments reveal chilli-sensitive molecular structure fluctuation changes in TRPV1

Retrieved on: 
Tuesday, May 9, 2023
Nobel Prize, National academy, 2021 Nobel Prize in Physiology or Medicine, PNAS, Transience, Ligand, TRPV1, Howard Hughes Medical Institute, Capsaicin, Temperature, Noetics, Pain, Fudan University, Literature, Protein, Thermodynamics, Nervous system, Science, AFM, Physiology, Kanazawa University, Microscope, Fine chemical

However, the mechanisms behind the function of TRPV1 have not been clear.

Key Points: 
  • However, the mechanisms behind the function of TRPV1 have not been clear.
  • Now Ayumi Sumino at Kanazawa University in Japan and Motoyuki Hattori at the Fudan University in China and their colleagues provide important insights into this mechanism.
  • Once activated, the TRPV1 channel opens, allowing ions to permeate and signalling to the nervous system that a noxious stimulant is present.
  • Antithetic effects of agonists and antagonists on the structural fluctuations of TRPV1 channel, Proceedings of the National Academy of Sciences May 8, 2023.

Kanazawa University research: Experiments reveal chilli-sensitive molecular structure fluctuation changes in TRPV1

Retrieved on: 
Tuesday, May 9, 2023
Nobel Prize, National academy, 2021 Nobel Prize in Physiology or Medicine, PNAS, Transience, Ligand, TRPV1, Howard Hughes Medical Institute, Capsaicin, Temperature, Noetics, Pain, Fudan University, Literature, Protein, Thermodynamics, Nervous system, Science, AFM, Physiology, Kanazawa University, Microscope, Fine chemical

However, the mechanisms behind the function of TRPV1 have not been clear.

Key Points: 
  • However, the mechanisms behind the function of TRPV1 have not been clear.
  • Now Ayumi Sumino at Kanazawa University in Japan and Motoyuki Hattori at the Fudan University in China and their colleagues provide important insights into this mechanism.
  • Once activated, the TRPV1 channel opens, allowing ions to permeate and signalling to the nervous system that a noxious stimulant is present.
  • Antithetic effects of agonists and antagonists on the structural fluctuations of TRPV1 channel, Proceedings of the National Academy of Sciences May 8, 2023.

Sorrento Therapeutics has Received FDA Clearance to Initiate Clinical Trials with a Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus

Retrieved on: 
Tuesday, December 6, 2022
Phase, Vaccination, Annual report, Degenerative disease, Nucleic acid, SAN, Security (finance), Cell Press, Antibody, Autoimmune disease, FDA, LNP, Omicron, PHN, Safety, US, CD8, Cancer, RNA transfection, JMCB, Delta, Pain, Trial of the century, Vaccine, Risk, Sciatica, Osteoarthritis, TRPV1, Time-invariant system, Mutation, Severe acute respiratory syndrome coronavirus 2, Therapy, RTX, Injection, Postherpetic neuralgia, Furin, Patient, Cell, IM, Pharmaceutical industry, Generic drug, Journal, COVID-19

SAN DIEGO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") has received clearance from the US FDA to initiate clinical trials with STI-1557, its next generation mRNA vaccine against SARS-CoV-2 Omicron variants.

Key Points: 
  • SAN DIEGO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") has received clearance from the US FDA to initiate clinical trials with STI-1557, its next generation mRNA vaccine against SARS-CoV-2 Omicron variants.
  • Sorrento plans to pursue more advanced mRNA vaccine strategies in the future with the Sofusa MuVaxx lymphatic delivery system.
  • Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19.
  • ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc.
    All other trademarks are the property of their respective owners.

Sorrento Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology (ESMO)

Retrieved on: 
Monday, December 5, 2022
Samsung Medical Center, Phase, ESMO, Extranodal NK/T-cell lymphoma, nasal type, Annual report, SAN, Incidence, Immunoglobulin G, Partnership, Security (finance), Antibody, Autoimmune disease, FDA, PHN, Safety, Cancer, Congress, PD-1, Pain, Trial of the century, RTX, Risk, ADCC, Recurrence, Vaccine, European Society for Medical Oncology, Principal, Sciatica, CD47, Osteoarthritis, Toxicity, Oncology, Radiation, TRPV1, FC, Therapy, Postherpetic neuralgia, Patient, PD-L1, Pharmaceutical industry, Generic drug, COVID-19

ImmuneOncia is a biotechnology company specializing in immuno-oncology drug development, jointly established by Yuhan Corporation of Korea and Sorrento .

Key Points: 
  • ImmuneOncia is a biotechnology company specializing in immuno-oncology drug development, jointly established by Yuhan Corporation of Korea and Sorrento .
  • The Phase II NK/T-cell lymphoma study was selected for an oral presentation at the Asian Congress of the European Society for Medical Oncology (ESMO Asia 2022) in Singapore on December 4th, 2022.
  • Due to the absence of standard-of-care treatment for relapsed/refractory cases, NK/T lymphoma represents a high unmet medical need and significant market opportunity.
  • RTX has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients.